Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
NCT ID: NCT04781387
Last Updated: 2025-06-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
43 participants
INTERVENTIONAL
2021-01-05
2024-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
NCT02106338
Phase I Trial of a Single Dose of CRS3123
NCT01551004
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
NCT07221708
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
NCT01259726
Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
NCT02951702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRS3123 200 milligram
CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.
Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm.
CRS3123
Study drug dosed PO BID for a total of 10 days
CRS3123 400 milligram
CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.
Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm.
CRS3123
Study drug dosed PO BID for a total of 10 days
Vancomycin 125 milligram
Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.
Active Comparator
Active comparator dosed PO QID for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CRS3123
Study drug dosed PO BID for a total of 10 days
Active Comparator
Active comparator dosed PO QID for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. More than or equal to 3 diarrheal (Bristol Stool Scale scores 5, 6, or 7) stools/day in a 24-hour period during screening prior to randomization and in the judgment of the investigator that C. difficile is the likely causative agent for the diarrhea.
3. Stool positive for C. difficile Toxin A and/or B antigen using an FDA or Health Canada approved/cleared EIA or ELISA laboratory test.
4. Participants with a primary episode or first recurrence of CDI are eligible.
5. In the judgment of the investigator, the expectation that the participant will survive with effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study.
6. Female participants of childbearing potential must not be pregnant, plan to become pregnant during the study, or be breastfeeding; and must be willing to commit to either sexual abstinence or use highly effective methods of birth control contraception from screening through Day 70.
7. Males must use a condom and spermicide from screening through Day 70 (if the female partner(s) is of childbearing potential) and must not donate sperm from screening through Day 70.
8. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
1. Intractable vomiting preventing oral medication intake
2. Severe underlying disease with an expected survival time less than the duration of the study (approximately 70 days).
3. More than 1 prior CDI occurrence within the last 3 months or more than 2 prior episodes of CDI in the last 12 months.
4. A history of a recent CDI episode within 3 months prior to enrollment that was non- responsive to vancomycin.
5. In the investigator's opinion, the participant is anticipated to require oral or intravenous systemic antibiotic therapy for a non-CDI infection between screening and Day 70.
6. Inflammatory bowel disease (Crohn's disease or ulcerative colitis), uncorrected Hirschsprung's disease, short gut syndrome, or any other condition known to significantly impact bowel motility and/or malabsorption.
7. Any other known pathogen associated with diarrhea.
8. Life-threatening or fulminant CDI as defined by IDSA/SHEA Guidelines.
9. Colonic perforation.
10. Need for concurrent laxatives or tube feeds, toxin binders, bile acid sequestrants during the study. Microbiota restoration therapy (MRT) or any phage therapy within 1 year of randomization. Receipt of bezlotoxumab within 3 months of randomization.
11. Participants treated with another antimicrobial agent directed at the current episode of CDI (metronidazole, fidaxomicin, rifaximin, tigecycline, or oral vancomycin) for \>24 hours of treatment within the 3 days prior to randomization will not be eligible for enrollment.
2. Pregnant or breastfeeding women.
3. Receipt of any investigational medication during the last month (30 days or 5 half lives, whichever is longer) prior to randomization.
4. Active and uncontrolled HIV with CD4 \<200/mm3.
5. Presence of active malignancy undergoing chemotherapy that is expected to cause significant immunosuppression, hematologic malignancy undergoing induction chemotherapy, or recent bone marrow or solid organ transplant (within 1 month prior to randomization) undergoing treatment with medications for the rejection of transplantation. In the investigator's opinion, is expected not to survive through the duration of the study (approximately 70 days) due to complications of the malignancy, or in the investigator's opinion will require oral or intravenous systemic antibiotic therapy during the study for malignancy related conditions.
6. Severe neutropenia defined as ANC \<500 cells/mm3
7. Severe hepatic impairment at screening including clinical signs of cirrhosis, end-stage hepatic disease (eg, ascites, hepatic encephalopathy), or Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x upper limit of normal (ULN) or total bilirubin ≥ 2x ULN.
8. Any other surgical or medical condition (including a clinically significant laboratory abnormality) as determined by the investigator or the medical monitor, that could interfere with the participant's ability to participate in the study, the administration of study treatment, and/or the interpretation of study results that, in the investigator's opinion, may confound study assessments or study procedures.
9. Known hypersensitivity to CRS3123 or oral vancomycin.
10. An employee of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as a family member of the employee or the investigator.
11. Unwillingness to stop consuming non-dietary probiotics from randomization to Day 70.
12. Participants currently taking digoxin within 1 week of screening.
13. Unwillingness to refrain from consumption of grapefruit and its juices as well as nutraceutical supplements containing curcumin from randomization until 24 hours after EOT.
14. Unwillingness to stop use of anti-diarrheals from randomization to Day 70.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Crestone, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Urs Ochsner, PhD
Role: PRINCIPAL_INVESTIGATOR
Crestone, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
131
Fullerton, California, United States
117
Lancaster, California, United States
143
Mission Hills, California, United States
138
Orange, California, United States
146
Miami, Florida, United States
122
Miami, Florida, United States
140
Marietta, Georgia, United States
110
Idaho Falls, Idaho, United States
129
Winfield, Illinois, United States
130
Royal Oak, Michigan, United States
139
Weldon Spring, Missouri, United States
128
Butte, Montana, United States
134
The Bronx, New York, United States
147
Chapel Hill, North Carolina, United States
114
Uniontown, Pennsylvania, United States
104
Cedar Park, Texas, United States
123
Houston, Texas, United States
101
San Antonio, Texas, United States
116
Calgary, Alberta, Canada
120
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
75N93019C00056
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
19-0021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.